Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Pancreatic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Pancreaticobiliary Neoplasm
Pancreatic Neoplasm

Subtype

Pancreatic Neoplasm

CI-CAN-00001356Explore in graph →

Non-malignant987 active trials8 approved drugs63 evidence items

NCIt: C3305
MeSH: D010190

Overview
Statistics
Survival
Genomics19
Variants & evidence63
Drugs32
Trials4216
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (218)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 26, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 151–175 of 218 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Defactinib inhibits focal adhesion kinase to attenuate pancreatic cancer growth via PI3K/AKT pathway modulation.
Hui-Deng Long, Hao Wang, Wei Xiang et al. · Biochim Biophys Acta Mol Basis Dis · Sep 2, 2026 · PMID 42685810 · candidate dictionary pubmed
An Exosomal Signature for Preoperative Detection of Occult Liver Metastasis in Pancreatic Cancer.
Takayuki Noma, Jingyang Yin, Junfeng Zhang et al. · JAMA Surg · Sep 2, 2026 · PMID 42684725 · candidate dictionary pubmed
Systemic treatment of advanced pancreatic cancer: A Comprehensive Review.
Jamshed Ali, Maria Qubtia, Amer Rehman Farrooqi et al. · J Cancer Allied Spec · Mar 1, 2026 · PMID 42725320 · candidate dictionary pubmed
Analgesic patterns and predictors of opioid consumption following epidural analgesia discontinuation after pancreatic cancer surgery.
Samuel Fredriksson, Christina Biörserud, Johanna Wennerblom et al. · Scand J Pain · Jan 1, 2026 · PMID 42714852 · candidate dictionary pubmed
Computational and experimental evaluation of curcumin as a DNMT3B-targeting epigenetic modulator in pancreatic cancer.
Ali Afgar, Saeed Zanganeh, Roohollah Mirzaee Khalilabadi et al. · In Silico Pharmacol · Jan 1, 2026 · PMID 42707300 · candidate dictionary pubmed
Patient-specific integration of RNA expression, methylation-derived replication-timing proxies, and histomorphology for pancreatic cancer subtyping.
Alejandro Leyva, M Khalid Khan Niazi · PLoS One · Jan 1, 2026 · PMID 42743314 · candidate dictionary pubmed

Showing 151–175 of 218 publications

← Previous
1
…
6
7
8
9
Next →

Machine learning-supported identification of necrosis in colorectal and pancreatic cancer spheroids.

Miguel Martínez Lozano, Heinz D Wanzenboeck, Sonia Prado-López · PLoS One · Jan 1, 2026 · PMID 42743162 · candidate dictionary pubmed

Differences of Statin Activity in 2D and 3D Pancreatic Cancer Cell Cultures [Expression of Concern].

· Drug Des Devel Ther · Jan 1, 2026 · PMID 42787175 · candidate dictionary pubmed

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

· N Engl J Med · 2019 · PMID 31157963 · validated civic_curation pubmed

Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.

· N Engl J Med · 2025 · PMID 39908431 · validated civic_curation pubmed

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

· Eur J Cancer · 2014 · PMID 24915778 · validated civic_curation pubmed

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.

· Mol Cancer Ther · 2011 · PMID 21862683 · validated civic_curation pubmed

Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.

· J Gastroenterol · 2013 · PMID 22983505 · validated civic_curation pubmed

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.

· Clin Transl Gastroenterol · 2016 · PMID 27010960 · validated civic_curation pubmed

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

· J Clin Oncol · 2015 · PMID 25366685 · validated civic_curation pubmed

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.

· Br J Cancer · 2014 · PMID 25072261 · validated civic_curation pubmed

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.

· Br J Cancer · 2012 · PMID 22374460 · validated civic_curation pubmed

Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu.

· Cancer Invest · 2004 · PMID 15581051 · validated civic_curation pubmed

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

· J Clin Oncol · 2018 · PMID 29320312 · validated civic_curation pubmed

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.

· Gastroenterology · 2012 · PMID 22705007 · validated civic_curation pubmed

SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.

· Clin Cancer Res · 2009 · PMID 19584151 · validated civic_curation pubmed

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.

· J Gastroenterol · 2013 · PMID 23435671 · validated civic_curation pubmed

CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.

· Oncotarget · 2016 · PMID 26894380 · validated civic_curation pubmed

High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma.

· BMC Cancer · 2013 · PMID 24088390 · validated civic_curation pubmed

The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma.

· Clin Cancer Res · 2001 · PMID 11751510 · validated civic_curation pubmed